Holen Sie sich die Stockscreener-App
14.64
1.57%
-0.325
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.96
Offen:
$15.07
24-Stunden-Volumen:
1.74M
Relative Volume:
0.70
Marktkapitalisierung:
$1.00B
Einnahmen:
$1.01B
Nettoeinkommen (Verlust:
$-204.71M
KGV:
-4.7701
EPS:
-3.0691
Netto-Cashflow:
$-29.67M
1W Leistung:
+6.28%
1M Leistung:
-27.65%
6M Leistung:
-28.94%
1J Leistung:
-28.91%
1-Tages-Spanne:
$14.65
$15.35
1-Wochen-Bereich:
$13.61
$15.92
52-Wochen-Spanne:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
14.66 | 1.03B | 1.01B | -204.71M | -29.67M | -3.0691 |
ABT
Abbott Laboratories
|
86.65 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.23 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.82 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.81 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.73 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Hochstufung | Truist | Hold → Buy |
| 2026-03-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Hochstufung | Lake Street | Hold → Buy |
| 2026-02-20 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Buy |
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
TNDM stock down following Q1 earnings & revenue beat, gross margin up - MSN
Tandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed? - Yahoo Finance
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 5.1% Drop? GF Value Says Undervalued - GuruFocus
Tandem Diabetes Care (TNDM) chair emeritus reports new RSU grant and vesting - Stock Titan
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Tandem Diabetes (TNDM) director reports 10,220 RSU grant and 8,759-share vesting - Stock Titan
Tandem Diabetes Care (TNDM) director receives 5,110 restricted stock units grant - Stock Titan
Tandem Diabetes (TNDM) director adds shares through RSU grant and vesting - Stock Titan
Director at Tandem Diabetes (NASDAQ: TNDM) adds RSUs and shares - Stock Titan
Tandem Diabetes (TNDM) director receives 10,220 RSU grant as prior award vests - Stock Titan
Tandem Diabetes (TNDM) director gets 10,220 RSUs as 8,759 vest - Stock Titan
Tandem Diabetes (TNDM) director Twomey reports RSU grant and 8,759-unit vesting - Stock Titan
Does Tandem Diabetes Care’s (TNDM) Expanded Incentive Plan Clarify Its Long‑Term Growth Priorities? - Sahm
Shareholders back charter changes and equity plan at Tandem Diabetes (NASDAQ: TNDM) - Stock Titan
Reasons to hold Tandem Diabetes stock in your portfolio for now - MSN
TNDM Technical Analysis | Trend, Signals & Chart Patterns | TANDEM DIABETES CARE INC (NASDAQ:TNDM) - ChartMill
Small-Cap Stocks to Avoid: Wyndham, KBR, and Tandem Diabetes Care AnalysisNews and Statistics - IndexBox
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds By Investing.com - Investing.com Nigeria
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds - Investing.com
Tandem Diabetes (NASDAQ: TNDM) Form 144: 266 RSUs slated for sale - Stock Titan
Tandem Diabetes Care Stock Down 23% But Insiders Still In US$84k Profit - 富途牛牛
Tandem Diabetes (TNDM) CTO reports RSU vesting, ESPP share purchase and tax withholding - Stock Titan
Tandem Diabetes (TNDM) EVP reports RSU exercises, tax share withholding and trust holdings - Stock Titan
Tandem Diabetes Care (TNDM) legal chief reports RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) COO logs RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) exec gains shares via RSU vesting and ESPP - Stock Titan
Tandem Diabetes Care (TNDM) CEO reports RSU vesting, ESPP buy and tax withholding - Stock Titan
Tandem Diabetes (TNDM) CFO exercises RSUs and ESPP, increases share holdings - Stock Titan
Tandem Diabetes (TNDM) EVP gets RSU shares while company withholds stock for taxes - Stock Titan
Silver Economy Investing: Why the Healthcare Giants Are in Focus - TradingView
TNDM Maintained by B of A Securities -- Price Target Lowered to $25 - GuruFocus
Tandem Diabetes Care Price Target Cut to $25.00/Share From $35.00 by B of A Securities - Moomoo
Tandem Diabetes’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $25 - Moomoo
Tandem Diabetes Care, Inc. Stock 12‑Month Price Target Cut to $30.8, Implies 140% Upside - TradingView
(TNDM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tandem Diabetes Care (TNDM) loses 26.5% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Tandem Diabetes Care, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Tandem Diabetes Care to end employment of chief commercial officer By Investing.com - Investing.com Canada
Tandem Diabetes Care to end employment of chief commercial officer - Investing.com UK
Tandem Diabetes Care Announces Leadership Change, Strategy Unchanged - TipRanks
Tandem Diabetes Care IncMark Novara, evp and chief commercial officer, to be terminated without causeSEC filing - marketscreener.com
Mark Novara to Exit Tandem Diabetes Care as EVP & Chief Commercial Officer - TradingView
Tandem Diabetes (NASDAQ: TNDM) to terminate EVP & Chief Commercial Officer - Stock Titan
Tandem Diabetes Care, Inc. Announces Termination of Mark Novara as Executive Vice President and Chief Commercial Officer, Effective May 18, 2026 - marketscreener.com
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up - TradingView
Tandem Diabetes Care Q1 earnings call highlights - MSN
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? - TradingView
Benchmark initiates coverage of Tandem Diabetes Care (TNDM) with hold recommendation - MSN
Transcript : Tandem Diabetes Care, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 02 - marketscreener.com
Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today - Yahoo Finance
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tandem Diabetes Care Inc-Aktie (TNDM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Howell Peyton R | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
29,836 |
| Malagueira Joao Paulo Falcao | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
22,458 |
| Sodhi Rajwant | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
24,280 |
| McGroddy-Goetz Kathleen | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
26,612 |
| ROBERTSON REBECCA B | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
22,542 |
| TWOMEY CHRISTOPHER J | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
24,434 |
| Cha Myoungil | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
22,458 |
0.32%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):